Evidence map›Paper›PMID 25867256›Full record

ArticleBritish journal of cancer2015

Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network.

A Smith, S Crouch, S Lax, J Li, D Painter, D Howell, R Patmore, A Jack, E Roman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 217 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
217citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

217 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Guideline
  2. Effectiveness ofWorld journal of gastroenterology · 2023
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

157 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

A SmithEpidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, YO10 5DD, UK.
S CrouchEpidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, YO10 5DD, UK.
S LaxEpidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, YO10 5DD, UK.
J LiEpidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, YO10 5DD, UK.
D PainterEpidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, YO10 5DD, UK.
D HowellEpidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, YO10 5DD, UK.
R PatmoreQueens Centre for Oncology, Castle Hill Hospital, Hull HU16 5JQ, UK.
A JackSt James's Institute of Oncology, Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF, UK.
E RomanEpidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, YO10 5DD, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPopulation-based information about cancer occurrence and survival are required to inform clinical practice and research; but for most lymphomas data are lacking.

methodsSet within a socio-demographically representative UK population of nearly 4 million, lymphoma data (N=5796) are from an established patient cohort.

resultsIncidence, survival (overall and relative) and prevalence estimates for >20 subtypes are presented. With few exceptions, males tended to be diagnosed at younger ages and have significantly (P<0.05) higher incidence rates. Differences were greatest at younger ages: the <15 year male/female rate ratio for all subtypes combined being 2.2 (95% CI 1.3-3.4). These gender differences impacted on prevalence; most subtype estimates being significantly (P<0.05) higher in males than females. Outcome varied widely by subtype; survival of patients with nodular lymphocyte predominant Hodgkin lymphoma approached that of the general population, whereas less than a third of those with other B-cell (e.g., mantle cell) or T-cell (e.g., peripheral-T) lymphomas survived for ≥5 years. No males/female survival differences were detected.

conclusionsMajor strengths of our study include completeness of ascertainment, world-class diagnostics and generalisability. The marked variations demonstrated confirm the requirement for 'real-world' data to inform aetiological hypotheses, health-care planning and the future monitoring of therapeutic changes.

Indexed as

AdolescentAdultAgedChildChild, PreschoolCohort StudiesFemaleFollow-Up StudiesHematologic NeoplasmsHumansIncidenceInfantInfant, NewbornLymphomaMaleMiddle Aged

Identifiers

PMID25867256
PMCPMC4453686

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.